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Maximizing baseline function of human pluripotent
stem cell-derived cardiomyocytes (hPSC-CMs) is
essential for their effective application in models of
cardiac toxicity and disease. Here, we aimed to iden-
tify factors that would promote an adequate level of
function to permit robust single-cell contractility
measurements in a human induced pluripotent
stem cell (hiPSC)model of hypertrophic cardiomyop-
athy (HCM). A simple screen revealed the collabora-
tive effects of thyroid hormone, IGF-1 and the
glucocorticoid analog dexamethasone on the elec-
trophysiology, bioenergetics, and contractile force
generation of hPSC-CMs. In this optimized condi-
tion, hiPSC-CMs with mutations in MYBPC3, a gene
encoding myosin-binding protein C, which, when
mutated, causes HCM, showed significantly lower
contractile force generation than controls. This was
recapitulated by direct knockdown of MYBPC3 in
control hPSC-CMs, supporting a mechanism of hap-
loinsufficiency. Modeling this disease in vitro using
human cells is an important step toward identifying
therapeutic interventions for HCM.
INTRODUCTION
Human pluripotent stem cells (hPSCs) are becoming increas-
ingly used in biomedical research. Their extensive growth and
differentiation potential enables routine production of cell types
otherwise difficult to obtain. Cardiomyocytes are an important
example, since collecting biopsies from the heart is highly inva-
sive, yet the cells they contain are those most pertinent to heart
disease and drug-associated toxicity. Although many reports
have now demonstrated the utility of hPSC-derived cardiomyo-
cytes (hPSC-CMs) for modeling heart disease (Bellin et al.,C2013; Drawnel et al., 2014; Wang et al., 2014; Zhang et al.,
2014), the baseline functional performance of these cells is still
less than that in adult heart tissue. Low maximum diastolic po-
tential (MDP) and slow action potential upstroke velocities are
frequently observed across all cardiomyocyte subtypes (Sartiani
et al., 2007; Zhang et al., 2009), coupled with a low force of
contraction (Hazeltine et al., 2012; Ribeiro et al., 2015).
The poor functional output of hPSC-CMs is in large part due to
their developmental immaturity (Veerman et al., 2015). While ef-
forts are ongoing to advance the developmental state beyond
their fetal equivalents, another important and valid approach is
to also consider ways to maximize cell function more immedi-
ately, which might not necessarily be coupled to or regulated
in the same way as developmental maturation. This might be
achieved, for example, by improving aspects of cell metabolism
and bioenergetics. Cardiomyocytes maintained outside their
native environment within the heart may be disconnected from
many factors important for their basic physiology, including rele-
vant growth factor and hormone signaling, extracellular matrix
proteins, other cell populations in the heart and mechanical
and electrical stimulation. As protocols for hPSC-CM generation
have improved and the generation of pure populations of cardi-
omyocytes in serum-free media has become well established,
this separation becomes evenmore notable. Many physiological
factors that would normally be circulating in the heart are absent
under most basal culture conditions, and it is unclear which
should be provided in a defined formulation to promote optimal
cardiomyocyte function in bioassay development.
The MDP is a fundamental determinant of excitability and in
cardiomyocytes from adult ‘‘working myocardium’’ is around
85 mV (Magyar et al., 2000). The lack of Ik1 current due to
low expression of theKCNJ2 gene is one reason that ventricular-
and atrial-like cardiomyocytes from hPSCs are insufficiently
polarized (Ma et al., 2011; Sartiani et al., 2007; Synnergren
et al., 2012). However, many other factors affect the resting
membrane potential. These include the activity of the energy
demanding Na,K-ATPase and potassium conductance as deter-
mined by other channels, which may also not be appropriatelyell Reports 13, 733–745, October 27, 2015 ª2015 The Authors 733
expressed or function optimally. TheMDP is a strong predictor of
contractile output in hPSC-CMs (Ribeiro et al., 2015), and
so improving MDP is an important prerequisite for faithfully
modeling diseases affecting excitability or contractility.
One disease predicted to affect cardiomyocyte contractility is
hypertrophic cardiomyopathy (HCM). HCM is highly prevalent,
affecting 1:500 of the population and can be caused by muta-
tions in various sarcomeric protein encoding genes (Maron and
Maron, 2013). Approximately 50% of cases are the result of
mutations either in MYH7, encoding b-myosin heavy chain, or
in MYBPC3, encoding cardiac myosin-binding protein C
(cMyBP-C). As a disease with known genetic cause but ill-
defined molecular pathogenesis, HCM is an excellent candidate
for stem cell modeling (Eschenhagen et al., 2015). The absence
of a cure or even an effective treatment strategy provides great
urgency for in vitro human models to identify drugs able to
restore contractile function and prevent the development of hy-
pertrophy, cardiac remodeling, and consequential arrhythmias.
Human induced pluripotent stem cells (hiPSCs) have already
been generated from patients with mutations in MYH7 and
MYBPC3, and cardiomyocytes derived from them (Dambrot
et al., 2014; Han et al., 2014; Lan et al., 2013), but their force gen-
eration, measured on physiologically relevant substrate dimen-
sions and stiffness, has not yet been described and is currently
hindered by poor baseline performance as noted above.
In this study, we began with a well-characterized NKX2-
5eGFP/w human embryonic stem cell (hESC) line, in whichworking
cardiomyocytes are specifically marked by eGFP expression
(Birket et al., 2015; Elliott et al., 2011), to identify factors or com-
binations of factors, which promoted an increase in their resting
plasmamembrane potential, or that had an anabolic effect, mak-
ing the assumption that such factors could have functional
benefit. We then tested these factors at the level of single-cell
traction force and action potential generation. Optimized condi-
tions were then applied to an hiPSC model of cMyBP-C insuffi-
ciency, and this revealed a contractile defect in cardiomyocytes
derived from MYBPC3 mutation carriers, which was mimicked
by knockdown of MYBPC3 in hESC-derived cardiomyocytes.
RESULTS
The Identification of Factors Modulating hPSC-Derived
Cardiomyocyte Plasma Membrane Potential and Size
Populations of cardiomyocytes were generated by monolayer
differentiation of NKX2-5eGFP/w hESCs, and these were main-
tained until day 16. To screen for modulators of resting plasma
membrane potential (DJp), we assessed short-term accumula-
tion of the cationic fluorescent probe tetramethylrhodamine
methyl ester (TMRM) in cell suspensions. TMRM follows Nerns-
tian behavior across cell membranes, the early phase of TMRM
accumulation into cells is dominated by the DJp, while with
longer loading times the mitochondrial membrane potential
and matrix volume contribute increasingly to total accumulation
(Gerencser et al., 2012). Time-course measurement of TMRM
accumulation was performed from control conditions (Figures
1A and 1B). Based on this, 8-min loading time was chosen for
relative assessments of DJp, since this was in the linear phase
of accumulation but gave signal substantially above back-734 Cell Reports 13, 733–745, October 27, 2015 ª2015 The Authorsground. Additionally, total cellular eGFP fluorescence was
used as an estimate of cell size/volume, on the assumption
that eGFP levels should correlate with total cell protein. There
are several caveats to this reasoning, but modulators can be
subsequently validated with more direct assays. In support of
a general correlation, fetal calf serum exposure, known to in-
crease the size of these cells (Birket et al., 2013), increased
eGFP levels after 5 days of exposure (Figure S1).
The following factors, each with putative roles in cardiomyo-
cyte function, were tested: insulin-like growth factor 1 (IGF-1),
the hedgehog signaling agonist SAG, the synthetic glucocorti-
coid dexamethasone (Dex), triiodothyronine hormone (T3), the
a-adrenergic agonist phenylephrine (PE), and the b-adrenergic
agonist isoproterenol (ISO) (El-Armouche and Eschenhagen,
2009; Bisping et al., 2012; Clement et al., 2009; Li et al., 2014;
Rog-Zielinska et al., 2015; Troncoso et al., 2014). Testing was
performed in a serum-free, low-insulin medium that has become
a widely used standard for maintenance of these cells (Ng et al.,
2008). Contracting monolayers of differentiated cells (day 16)
were maintained for 5 days in each test condition before mea-
surement (Figure 1C). IGF-1 was the only factor to significantly
increase eGFP fluorescence intensity, and TMRM accumulation
increased only proportionally in this condition. IGF-1 may there-
fore mildly increase cell volume without affecting DJp. T3 was
the only factor that significantly increased TMRM accumulation,
while eGFP fluorescence remained unaffected. This indicated an
increase in DJp by T3, but not in cell volume. While ISO mildly
increased TMRM accumulation, neither ISO nor PE induced an
increase in eGFP fluorescence; inconsistent with their estab-
lished role as hypertrophic agonists in other cardiomyocyte sys-
tems but consistent with a reported variable response in some
hPSC-CM lines (Fo¨ldes et al., 2014; Vidal et al., 2012; Zhang
et al., 2013). Dex had little effect on either eGFP or TMRM,
consistent with unpublished work from our group showing a
lack of effect by Dex-alone on cardiomyocyte electrophysiology
in hPSC-derived cardiomyocytes (G.K., C.L.M., M. Bellin, B. van
Meer, L. Tertoolen, and S. Casini, unpublished data), but in-
consistent with its previously described role in cardiomyocyte
maturation (Rog-Zielinska et al., 2013, 2015), suggesting that
competence factors may be lacking.
These results support a role for T3 in determining DJp in
hPSC-derived cardiomyocytes, but not for maturation-related
growth. To explore the possibility of enhancing this condition
further, we tested the effect of additional IGF-1 or Dex compared
to T3-alone (assigned as the new reference control and normal-
ized to 1) (Figure 1D). The addition of IGF-1 again mildly
increased eGFP levels over T3-alone, while T3+Dex mildly, but
significantly, increased TMRM accumulation. However, the
combination of T3+IGF-1+Dex (TID) increased both eGFP and
TMRM significantly, suggesting an enhancement in both size
and possibly DJp (Figure 1E), which could be associated with
further improved cardiomyocyte function. The increased eGFP
fluorescence with T3+IGF-1 and TID was not associated with,
and therefore explained by, a relative increase in eGFP mRNA
expression in these cells (Figure S2). Upregulation (4-fold) of
the glucocorticoid-response gene FKBP5 confirmed increased
glucocorticoid signaling by Dex (Figure S2). The action of TID
on eGFP levels and TMRM accumulation was confirmed in
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Figure 1. Using TMRM to Identify Modifiers
of DJp in hESC-Derived NKX2-5+ Cardio-
myocytes
(A) Time-course measurement of TMRM accumu-
lation after cardiac differentiation of NKX2-5eGFP/w
hESCs. fluorescence-activated cell sorting (FACS)
plots show eGFP and TMRM fluorescence after 0,
4, 8, 13, and 22 min of loading with TMRM. Aminor
cross-bleed correction has been applied to all.
(B) Median TMRM fluorescence intensity in eGFP+
cells plotted against loading time.
(C) eGFP and TMRM fluorescence values in eGFP+
cardiomyocytes relative to a vehicle-only control
after 5 days of incubation with the factors shown
(n = 6–34).
(D) eGFP and TMRM fluorescence values in eGFP+
cardiomyocytes relative to a T3-treated control
after 5 days of incubation with the factors shown
(n = 10–22).
(E) Upper panel: example FACS plots showing
measurement of a vehicle-only control alongside a
T3+IGF-1+Dex-treated sample. Lower panel: his-
tograms of eGFP and TMRM intensity in the eGFP+
populations as marked on the dot plots above.
(F) eGFP and TMRM fluorescence values in eGFP+
cardiomyocytes relative to a T3+IGF-1+Dex-
treated sample after 5 days of incubation with the
factors shown (n = 11).
Data are mean ± SEM. The n signifies biological
replicates. Statistical significance compared to the
vehicle-only control was calculated using a one-
way ANOVA with Dunnett’s correction, #p < 0.05
for eGFP fluorescence; *p < 0.05 for TMRM fluo-
rescence. See also Figures S1 and S2.cardiomyocytes from an independent NKX2-5eGFP/w knockin re-
porterM1 hESC line aswell as anNKX2-5eGFP/w knockin reporter
hiPSC line (Figure S1).
Given that insulin was present in the basal medium at 1 mg/ml
for all these assays and at these concentrations can cross-react
with the IGF-1 receptor, we separately tested the impact of insu-
lin and IGF-1 in this T3+Dex condition. Addition of 1 mg/ml insu-
lin-alone to the medium containing T3+Dex significantly
increased eGFP fluorescence, but addition of 100 ng/ml IGF-1
increased eGFP fluorescence further and also increased
TMRM accumulation (Figure S1). This suggests that activation
of the IGF receptor is the primary mediator of this response.
Importantly, in the presence of TID, cardiomyocytes re-
sponded appropriately to stimulation by the adrenergic agonists
norepinephrine (NE), PE, or ISO, with an increase in eGFP fluo-
rescence, suggesting that a baseline level of bioenergetic orCell Reports 13, 733–745,anabolic activity may be important for
this hypertrophic response (Figure 1F).
Relative eGFP mRNA expression was
not significantly affected by these factors
(Figure S2). The action of adrenergic ago-
nists did not, however, increase TMRM
accumulation beyond the increase in
eGFP intensity, suggesting increased
TMRM was probably due to increasedcell volume and not due to a further improvement in DJp by
these factors.
Bioenergetic Response in Cardiomyocytes by the
Concerted Action of T3, IGF-1, and Dexamethasone
The response to IGF-1 and Dex in terms of cardiomyocyte
growth and DJp suggests a possible synergistic role in meta-
bolic stimulation. To test this, bioenergetic profiling of contract-
ing cardiomyocyte monolayers was performed using the
Seahorse XF Analyzer on cells treated during the same experi-
mental time course. Contraction rates, measured prior to anal-
ysis, were not significantly different between groups (Figure 2A).
Under standard conditions (15 mM glucose, 0.5 mM sodium
pyruvate) normalized to total cell protein, T3 mildly increased
the oligomycin-sensitive respiration rate as previously reported
(Yang et al., 2014), indicating increased mitochondrial ATPOctober 27, 2015 ª2015 The Authors 735
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Figure 2. Bioenergetic Profiling of hESC-Derived Cardiomyocytes
(A) Contraction frequency in cardiomyocyte monolayers, treated for 5 days with the factors shown, prior to Seahorse measurement.
(B) Respiration rates in cardiomyocytemonolayers treated with the factors shown, normalized to cell protein. Basal, endogenous rate; oligomycin, ATP synthase-
inhibited rate; FCCP, maximum uncoupled rate; Rot + Ant A, non-mitochondrial respiratory rate.
(C) Glycolytic rate measured in parallel with respiration, normalized to cell protein.
(D) Theoretical basal ATP production rates from oxidative phosphorylation and anaerobic glycolysis calculated from measurements in (B) and (C).
(E) Real-time respiration measurements of vehicle-only and TID-treated cells and response to injection of vehicle-only or nifedipine + blebbistatin, then oligo-
mycin, and finally rotenone and antimycin A.
(F and G) Real-time respiration measurements of (F) vehicle-only or (G) TID-treated cells and response to injection of vehicle-only or 40 mM etomoxir or 5 mM
UK5099, then oligomycin, FCCP, and finally rotenone and antimycin A.
(H) Sensitivity of basal and FCCP-stimulated mitochondrial respiration to etomoxir and UK5099 in vehicle-only or TID-treated cells.
Bar data are mean ± SEM from three independent experiments, each comprising four to five measurement wells per condition. Real-time respiration plots show
data of a typical experiment mean ± SD of individual wells. Statistical significance compared to the vehicle-only control was calculated using a one-way ANOVA
with Dunnett’s correction for (B)–(D). *p < 0.05. See also Figure S3.turnover (Figures 2B and 2D). Neither IGF-1 nor Dex stimulated
this further, but the combination of TID did have a further stimu-
latory effect (TID: 213 ± 4 versus vehicle: 124 ± 6 pmol O2/min/
10 mg cell protein; p < 0.05). The anaerobic glycolytic rate (calcu-736 Cell Reports 13, 733–745, October 27, 2015 ª2015 The Authorslated as previously described byMookerjee et al., 2015) was also
significantly increased by TID (TID: 68 ± 4 versus vehicle: 34 ±
4 pmol H+/min/10 mg cell protein; p < 0.05) (Figure 2C). A conver-
sion of these values to ATP production rates (see Experimental
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Figure 3. Cardiomyocyte Action Potential
Measurement
(A) Typical examples of action potential (AP) traces
from single spontaneously active cardiomyocytes
maintained in the three conditions indicated.
(B–G) Average data of maximum diastolic potential
(MDP), AP amplitude, AP upstroke velocity, and AP
duration at 50% (APD50) and 90% (APD90) repo-
larization and AP frequency. SGKi, 5-day co-in-
cubation with 6 mM GSK650394. Data are mean ±
SEM. Actual AP values and n values are shown in
Table 1. Statistical significance was calculated
using a one-way ANOVA with Tukey’s multiple
comparison test *p < 0.05.Procedures) showed a large increase (1.7-fold) in combined ATP
turnover with TID (Figure 2D). The oligomycin-inhibited rates, the
maximum uncoupled respiration rates induced by carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and the
non-mitochondrial rates were not significantly different between
conditions (Figure 2B). These results support a synergistic effect
for the actions of IGF-1 and Dex on basal cell activity. Inhibition
of both excitation and contraction by co-injection of nifedipine
and blebbistatin decreased the mitochondrial respiration rate
by 39.3% ± 4.2% in the vehicle-only condition and 43.9% ±
9.0% in TID (Figure 1E) after subtraction of a minor buffer-only
injection effect. As the starting respiration rate was higher with
TID, this showed that the activity of these processes had
increased at least proportionally by TID.
Sensitivity to substrate supply was assessed by examining the
change in basal respiration rate and respiratory capacity on inhi-
bition of either long-chain fatty acid uptake into mitochondria by
thecarnitine palmitoyl transferase inhibitor etomoxir (40mM)or in-
hibition of mitochondrial pyruvate uptake by inhibition of the py-
ruvate transporter with UK5099 (5 mM). These experimentsCell Reports 13, 733–745were performed in a more physiological
medium containing 5.5 mM glucose,
0.15 mM sodium pyruvate, and 100 mM
palmitate. Figures 2F and 2G show typical
respiratory responses to etomoxir and
UK5099of cells fromvehicle-onlymedium
and TID medium, respectively. Figure 2H
shows quantification of the sensitivity of
basal andFCCP-stimulatedmitochondrial
respiration rates to these inhibitors. Basal
respiration in cells from vehicle-only me-
dium, and TID medium was inhibited
21.0%±4.3%and24.4%±4.9%, respec-
tively, by etomoxir, and 27.7% ± 4.2%
and 31.9% ± 3.3%, respectively, by
UK5099. The basal respiration rate was
again higher in TID-treated cells. FCCP-
stimulated respiration in cells from
vehicle-only medium and TID medium
was inhibited 18.5% ± 2.1% and 20.2%
± 2.2%, respectively, by etomoxir, and
53.8%±5.5%and47.0%±2.9%, respec-
tively, byUK5099.Overall, thesedata sug-gest that TID increases the basal utilization of both glucose and
fatty acids in cardiomyocytes in concert with increased ATP de-
mand for excitation/contraction aswell as other processes. In line
with these changes, TID increased expression of PGC-1a and
PGC-1b (Figure S2), important regulators of myocardial fatty
acid oxidation (FAO) and mitochondrial function (Birket et al.,
2013; Finck and Kelly, 2007). We additionally found that
increased bioenergetic activity by TID exposure was associated
with a decreased rate of dihydroethidium (DHE) oxidation, sug-
gesting a decreased level of reactive oxygen species (Figure S3),
which may also support improved cardiomyocyte function.
Electrophysiological and Contractile Improvements by
the Concerted Action of TID
To test whether the bioenergetic changes and improved resting
DJp resulted in improvements in electrophysiological function,
action potentials were measured in spontaneously active cells.
To focus on a possible effect of glucocorticoid signaling, we
measured cells maintained in three conditions: vehicle-only,
T3+IGF-1, and TID. The results are shown in Figure 3 and, October 27, 2015 ª2015 The Authors 737
Table 1. Action Potential Parameters of Single Spontaneously
Active Cardiomyocytes
Vehicle
(n = 12)
T3+IGF-1
(n = 15)
T3+IGF-
1+Dex
(n = 33)
TID+SGKi
(n = 16)
MDP (mV) –66.9 ± 1.2 –71.5 ± 0.9a –74.2 ± 0.8a –74.2 ± 1.1a
dV/dtmax (V/s) 15.8 ± 2.2 21.5 ± 4.9 58.9 ± 4.6
a 36.5 ± 5.6
APA (mV) 97 ± 2 104 ± 2a 112 ± 2a 114 ± 2a
APD50 (ms) 110 ± 11 98 ± 12 104 ± 11 97 ± 10
APD90 (ms) 146 ± 14 125 ± 13 134 ± 11 124 ± 10
Frequency (Hz) 1.6 ± 0.2 2.1 ± 0.2 2.5 ± 0.2a 2.2 ± 0.2
Capacitance
(Cm)
20 ± 3 17 ± 1 25 ± 2 24 ± 3
Data are mean ± SEM; TID+SGKi = T3+IGF-1+Dex+GSK650394,
n = number of cells; MDP, maximal diastolic potential; dV/dtmax, maximal
upstroke velocity; APA, action potential amplitude; APD50 and APD90,
action potential duration at 50% and 90% repolarization, respectively.
ap < 0.05 compared to vehicle. One-way ANOVA with a Tukey post-test.summarized in Table 1. The MDP was increased by both
T3+IGF-1 and TID (Figure 3B), aligning well with our estimates
by TMRM uptake. The amplitude of the action potential (AP)
was also increased progressively by both treatments (Figure 3C).
Interestingly, while the upstroke velocity was not significantly
increased by T3+IGF-1 it was markedly increased by TID, from
16 ± 5 to 59 ± 6 V/s (Figure 3D; p < 0.05). This specific effect
was significantly blocked by 6 mM GSK650394, an inhibitor of
the serum- and glucocorticoid inducible kinase SGK1 (Sherk
et al., 2008), which was previously shown to block cardiac so-
dium channel degradation, and which is activated by IGF-1
(Boehmer et al., 2003). We confirmed SGK1 upregulation in
response to Dex (Figure 3G). SCN5A expression was not
increased by dexamethasone (Figure S2), and the inhibitor did
not significantly affect any other aspect of the AP, together sup-
porting this specific mechanistic explanation. Despite the
increased MDP, AP frequency was increased by TID in this sin-
gle-cell format (Figure 3F), differing from measurements in the
monolayer format in Figure 2A. In summary, the AP data also
support the conclusion that cardiomyocyte function was
improved by the action of TID.
Next, we examined single-cell contractility under the same
maintenance conditions with the exception that cardiomyocytes
were plated on soft micropatterned polyacrylamide gels (20-mm-
wide gelatin lines) containing fluorescent micro-beads. Bead
displacement was imaged during spontaneous contraction of
individual cells and converted to a value of traction stress
(Figure 4A), as previously described (Ribeiro et al., 2015).
In vehicle-only medium, mean traction stress was 0.15 ±
0.02 mN/mm2; in T3+IGF-1, this was increased by 1.8-fold to
0.27 ± 0.02 mN/mm2 (p < 0.05), and in TID medium it was
increased by 2.9-fold to 0.44 ± 0.04 mN/mm2 (p < 0.05) (Fig-
ure 4B). This corresponded to traction forces of 0.15 ± 0.02,
0.36 ± 0.04, and 0.76 ± 0.08 mN for vehicle-only, T3+IGF-1,
and TID medium, respectively. The potentiated increase in trac-
tion stress by the addition of Dex, over the T3+IGF-1 condition,
was significant (p < 0.05). Cardiomyocyte area was increased
1.4-fold by T3+IGF-1 (p < 0.05) and 1.8-fold by TID (p < 0.05)738 Cell Reports 13, 733–745, October 27, 2015 ª2015 The Authors(Figure 4C), although cells remained small compared to adult
human equivalents (Ancey et al., 2003). The potentiated increase
in cell area by Dex was significant (p < 0.05), aligning with
our estimates by eGFP intensity. Contraction frequency was
increased by TID; however, as the force-frequency relationship
was negative in all conditions, this did not explain the difference
in traction stress between the conditions (Figure 4D). Co-staining
of Troponin I and a-actinin showed that the structural organiza-
tion of sarcomeres was improved by TID and sarcomeres were
more uniform across the entire area of each cardiomyocyte (Fig-
ures 4E and S4). Expression of the contractility-related protein
encoding genesMYH6, ACTN2,MLC2V, and SERCA2 were up-
regulated by TID, although they were not significantly different
between T3+IGF-1 and TID (Figure S2). T3 repressed MYH7
expression as previously reported (Iwaki et al., 2014). An in-
crease in traction stress by TID was also recorded in cardiomyo-
cytes from the M1 hESC line (Figure S4).
Contractile Dysfunction in a hiPSC Model of
Hypertrophic Cardiomyopathy
We have previously observed that single hiPSC-derived cardio-
myocytes also generate very low contractile forces when main-
tained under standard basal conditions (0.2 mN/mm2) (Ribeiro
et al., 2015). This creates a very low level of sensitivity for detect-
ing defects in function, as even the control cells may be func-
tioning far from their full dynamic range. Therefore, we took the
opportunity to apply the TID-containing medium to an hiPSC
disease model in which the derivative cardiomyocytes carry a
c.2373dupG mutation in MYBPC3 (Dambrot et al., 2014). This
mutation causes HCM in patients (Alders et al., 2003). The
mutant MYBPC3 hiPSC-CMs were compared to cardiomyo-
cytes derived from two hiPSC lines generated from healthy con-
trols. Cardiac functional data of the HCMpatients are provided in
Table S1. A significant decrease in cMyBP-C protein relative to
a-actinin was observed in the cardiomyocytes from all three
HCM lines compared to both controls when measured at day
25 of differentiation (Figures 1A and 1B).
Attempts tomeasure these hiPSC-CMs inmediumwithout TID
proved unsuccessful as even the control cells failed to reliably
generate robust bead displacement. However, in medium con-
taining TID, traction force on the polyacrylamide substrate could
be measured in all cell populations. Under these conditions,
traction stress was significantly decreased in all three mutant
lines, HCM1 0.31 ± 0.02, HCM2 0.30 ± 0.03, HCM3 0.29 ±
0.03 mN/mm2 in comparison to both controls, Con1 0.57 ±
0.04 and Con2 0.51 ± 0.03 mN/mm2; p < 0.05 (Figures 5C and
5D). This corresponded to traction forces of 0.43 ± 0.04, 0.46 ±
0.06, 0.44 ± 0.05, 0.81 ± 0.16, and 0.86 ± 0.10 mN for HCM1,
HCM2, HCM3, Con1, and Con2, respectively. A difference in
cardiomyocyte size as measured by cell area was not evident
between the control and the mutant cells, suggesting an overt
hypertrophic response had not occurred by this stage of devel-
opment under these conditions (Figure 5E). Contraction fre-
quencies were not different (Figure S4).
Reports have suggested that the HCMphenotype is promoted
not by the mutated protein, which is not found in patients and
was not detected in the current cell lysates, but by a decrease
in the total level of wild-type cMyBP-C (haploinsufficiency) (van
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Figure 4. Single Cardiomyocyte Traction Force Measurement
(A) Typical examples of single aligned (spontaneously contracting) cardiomyocytes from vehicle-only and T3+IGF-1+Dex-containing medium, showing a bright-
field image of the relaxed form and a heatmap of traction stress applied to the substrate calculated from the mean of the traction stress vectors (corresponding to
Movie S1).
(B–D) (B) Traction stress, (C) cell area, and (D) traction stress-frequency relationship of single spontaneously contracting cardiomyocytes maintained in vehicle
(n = 44), T3+IGF-1 (n = 44), and T3+IGF-1+Dex (n = 45).
(E) Immunostaining of typical aligned cardiomyocytes from vehicle- and TID-containing medium.
Box and whisker plots show the median, interquartile range, and 10–90 percentile range. The n signifies the number of individual cells measured, acquired over
three independent experiments. Statistical significance was calculated using a one-way ANOVA with Tukey’s multiple comparison test *p < 0.05. Scale bar,
10 mm. See also Figure S4.Dijk et al., 2009; Moolman et al., 2000). To test whether the
decrease in traction force was indeed caused by the decreased
expression of cMyBP-C, we employed an RNAi approach in car-
diomyocytes derived from the NKX2-5eGFP/w hESC line. We
transduced hESC-CMs with lentiviruses expressing scrambled
or MYBPC3-specific short hairpin RNAs (shRNAs), selected
them with puromycin, and assessed the effect on contractile
force generation. Knockdown of cMyBP-C was confirmed at
the protein level (Figure 5F). For these experiments, we used car-
diomyocyte culture medium containing TID but further refined to
contain entirely defined basal components and to be serum
albumin free (see Experimental Procedures), these being impor-
tant considerations for future use. Increased NaHCO3 was also
included to increase buffering of the high carbonic and lactic
acid production of cardiomyocytes in TID. Dose-response tests
were performed with T3 and Dex, and traction stress was
compared to the previous formulation and found to be superior
(Figure S5). Under this condition, traction stress was significantly
decreased in cardiomyocytes expressing either of theMYBPC3-
shRNA constructs (Scr 0.90 ± 0.05 mN/mm2, shRNA1 0.47 ±
0.03 mN/mm2, and shRNA2 0.36 ± 0.03 mN/mm2; p < 0.05; cor-Cresponding to traction forces of 1.66 ± 0.11, 0.78 ± 0.07, and
0.70 ± 0.08 mN, respectively) (Figure 5G), while cell area was
not significantly affected (Figure 5H), nor was protein content
per cardiomyocyte as measured in bulk sorted populations
(Scr shRNA: 185 ± 33 ng/1,000 cells versus MYBPC3 shRNA
2: 189 ± 33 ng/1,000 cells). These results support the conclusion
that the phenotype observed in the patient-derived cells is
caused by the decreased level of cMyBP-C protein at a pre-
hypertrophic stage.
DISCUSSION
Using a simple flow cytometry based assay, we have identified a
combination of defined factors, namely, thyroid hormone (T3),
IGF-1, and the glucocorticoid dexamethasone, which together
enhanced the functional properties of hPSC-derived cardiomyo-
cytes. We observed that T3 principally increased the resting
membrane potential (DJp), a critical factor in determining ex-
citability and contractility, whereas IGF-1 and dexamethasone
acted synergistically to stimulate cell energetics and traction
force generation. In this optimized condition, we assessed theell Reports 13, 733–745, October 27, 2015 ª2015 The Authors 739
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impact of an HCM-causingmutation inMYBPC3, or gene knock-
down. Decreased force generation was observed in both cases,
recapitulating measurements in mutant mouse models and
patient-derived cells, opening up the possibility of using this in-
vitro-based humanmodel as a tool for futuremechanistic studies
and drug screening.
The positive influence of T3 on cardiomyocyte function is well
supported in the literature. Levels increase markedly at birth in
humans and have an important role in heart development and
maturation (Biondi and Klein, 2004; Li et al., 2014). T3 was previ-
ously shown to increase the activity of the Na,K-ATPase in car-
diomyocytes (Forini et al., 2004), as well as increasing the Ik1
current (Sakaguchi et al., 1996), both of which could explain
the increase in DJp observed here. T3 also affects sarcomeric
gene expression, stimulating expression of a-MHC, the fast
ATPase activity MHC isoform, and repressing the expression
of b-MHC, the slow ATPase activity isoform (Danzi et al., 2003;
Iwaki et al., 2014). This effect was also shown in hESC-CMs by
Yang et al. (2014) and confirmed here. These changes in MHC
isoform expression may contribute to the increased contractile
force generation observed with T3, as also previously reported
by Yang et al. (2014). However, from this base condition we
were able to extend these findings with the identification of addi-
tional physiologically relevant factors important for hPSC-CM
function. IGF-1 also circulates in the developing heart and has
an important role in myocardial cell growth and metabolism by
signaling through the IGF-1 tyrosine kinase receptor (Troncoso
et al., 2014). We found that IGF-1 mildly increased the size of
hPSC-CMs, but more importantly proved an essential factor in
revealing a positive functional role for the glucocorticoid dexa-
methasone in this system. Synergistic effects for IGF-1 and
dexamethasone have been reported in skeletal muscle and
heart, with pro-differentiation and anti-atrophic effects observed
(Chrysis et al., 2011; Pansters et al., 2013; Schakman et al.,
2008). Glucocorticoids also promote the structural and func-
tional maturation of fetal mouse cardiomyocytes (Rog-Zielinska
et al., 2013, 2015) but have little effect on hPSC-CMs when
added alone although do affect calcium handling (G.K., C.L.M.,
M. Bellin, B. van Meer, L. Tertoolen, and S. Casini, unpublished
data). Interestingly, the positive effect reported by Rog-Zielinska
et al. in cultured cells was blocked by PGC-1a knockdown, aFigure 5. Single-Cell Traction Force Measurements in Cardiomyocyte
(A) Western blot of cMyBP-C protein from two control (Con1 and Con2) and thre
loading control for cardiomyocyte input.
(B) Relative cMyBP-C levels normalized to a-actinin levels based on densitomet
(C) Typical examples of single aligned (spontaneously contracting) cardiomyocyt
field image of the relaxed form and a heatmap of traction stress applied to the sub
Movie S2).
(D and E) (D) Traction stress and (E) cell area of single spontaneously contracting iP
and three MYBPC3 mutation lines (HCM1 [n = 44], HCM2 [n = 54], and HCM3 [n
(F) Western blot of cMyBP-C protein in NKX2-5eGFP/w hESC-derived cardiomy
MYBPC3-specific shRNAs. Actin is shown as a loading control.
(G and H) (G) Traction stress and (H) cell area of single spontaneously contracting
MYBPC3-specific (1, n = 26; 2, n = 16) shRNAs.
Boxplots and whisker plots show the median, interquartile range, and 10–90 per
cells measured, acquired over three independent experiments. Statistical signific
in (D) and (E), comparing either control against the HCM lines independently, an
statistically significant *p < 0.05. Scale bar, 10 mm. See also Figure S5.
Cprotein known to regulate mitochondrial respiration in cardio-
myocytes (Birket et al., 2013). Our observation here, that in com-
bination with IGF-1 dexamethasone exerted a clear bioenergetic
response, also supports the conclusion that the functional im-
provements in force generation and electrophysiology may at
least partly be the result of enhanced energy production path-
ways. Basal respiration coupled to ATP synthesis was increased
by TID, and as this rate remained proportionally sensitive to in-
hibitors of excitation and contraction these processes must be
more active in these cells. Additionally, we showed that basal
respiration was sensitive to inhibitors of bothmitochondrial pyru-
vate uptake as well as fatty acid uptake, implying that substrate
supply also exerts significant respiratory control in both basal
and TID conditions. The higher respiratory rate in TID suggests
that both pyruvate and fatty acid usage was increased. TID
also stimulated anaerobic glycolysis, which will provide addi-
tional pyruvate for mitochondria but can also drive the synthesis
of biomass through precursor synthesis (Chen et al., 2015), and
increase NADPH production important for ROS detoxification
(Hamanaka and Chandel, 2011). Reduced DHE oxidation in cells
treated with TID indeed indicated lower ROS levels. Mitochon-
drial ROS production may also be lower as a result of the
increased ATP turnover (Goncalves et al., 2015). While ROS
have been shown to have an important role in cardiomyocyte
development (Puente et al., 2014), elevated levels can be inhib-
itory to cell function so a balance may be important (Birket et al.,
2013; Guerra et al., 1996; Liu et al., 2010).
At the electrophysiological level, in the presence of T3, the
addition of IGF-1 and dexamethasone caused a large increase
in hESC-CM AP upstroke velocity not explained solely by the
MDP. This was not associated with increased SCN5A expres-
sion and was therefore predicted to involve altered cardiac so-
dium channel regulation. The functional improvement was highly
sensitive to small molecule inhibition of the glucocorticoid-
inducible kinase SGK1 which is known to regulate degradation
of the channel through inactivation of the ubiquitin ligase
NEDD4-2 (Boehmer et al., 2003; Lang et al., 2014). This result
supports a role for SGK1 in hPSC-CM function and will be an
important avenue for future investigation. A further improvement
was seen in the AP amplitude by TID, a parameter known to
correlate with contractile force generation at a single-cell levels with MYBPC3 Mutation or MYBPC3 shRNA Knockdown
e MYBPC3 mutation lines (HCM1, HCM2, and HCM3). a-actinin is shown as a
ry of western blot data (n = 3–6 lysates).
es from control (Con1) and MYBPC3 mutation (HCM3) lines, showing a bright-
strate calculated from the mean of the traction stress vectors (corresponding to
SC-derived cardiomyocytes from two control (Con1 [n = 47] and Con2 [n = 36])
= 43]).
ocytes after transduction with a scrambled (Scr) shRNA or two independent
cardiomyocytes non-transduced (n = 15), stably expressing the Scr- (n = 32) or
centile range. Unless otherwise stated, the n signifies the number of individual
ance was tested with a one-way ANOVA with Tukey’s multiple comparison test
d a Dunnett’s correction in (G) and (H). Comparison to both controls in (D) are
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(Ribeiro et al., 2015). Indeed, TID substantially increased the
traction force of hPSC-CMs aswell as their sarcomeric structural
organization, showing that all core aspects of cell function were
enhanced.
Having identified conditions for maximizing traction force, we
were able to apply the system to a cardiac disease model. HCM
is caused by mutations in sarcomeric protein-encoding genes
important for contractile function, of which mutation inMYBPC3
accounts for approximately 20%–25% of cases. While animal
models of cMyBP-C deficiency and patient-derived cells have
been well studied (Barefield et al., 2015; van Dijk et al., 2009;
Harris et al., 2002; McConnell et al., 2001; Pohlmann et al.,
2007; Sto¨hr et al., 2013; Witjas-Paalberends et al., 2013), a
widely accessible human in vitro model has been lacking.
Here, using two independent approaches, we assessed the
impact of cMyBP-C deficiency on hPSC-CM contractile force
generation. Cardiomyocytes from patient-derived hiPSCs car-
rying a non-sense mutation in MYBPC3 had <50% of normal
cMyBP-C levels and were found to exert significantly less force
at the single-cell level. This result was also observed following
shRNA-mediated MYBPC3 knockdown in otherwise normal
cells. Our results are supported by measurements in adult pa-
tient-derived cells assessed in vitro where a 30%–40%decrease
in maximum Ca2+-activated force development has been
observed in cells with the c.2373insG mutation, and a mecha-
nism of haploinsufficiency suggested (van Dijk et al., 2009,
2014; Witjas-Paalberends et al., 2013). Importantly, the force
generation defects we observed here were in non-hypertrophic
cells, suggesting a primary event not consequential to hypertro-
phy and related maladaptive processes. This observation is
consistent with the diastolic dysfunction reported in non-hyper-
trophic cardiomyocytes of mice heterozygous for a point muta-
tion in mybpc3 (Fraysse et al., 2012). Together these results
support the possibility that the contractile dysfunction is an early
initiating event in HCM disease pathogenesis. The specific initi-
ating cause of the force generation defect in the hPSC-CMs
studied here is unknown, as in all other models ofMYBPC3mu-
tation studied so far. Potential causes could include a defect
in sarcomerogenesis leading to a reduced myofibril density,
perturbed cross bridge cycling or increased sarcomere cal-
cium sensitivity leading to diastolic dysfunction, or more general
metabolic disturbance. Having a human model where this
phenotype can be genetically induced and studied in a develop-
mental context will present new opportunities to address this
question. This could in turn lead to new therapeutic strategies
for HCM, which is currently without cure.
In summary, providing functionally important physiological
factors to hPSC-CMs may be critical for achieving robust
baseline function and maximizing their use in applications
of disease modeling, drug discovery and development, and
toxicity screening. These are major goals for the stem cell field.
Here, we found that three defined factors were sufficient to
markedly improve the function of hPSC-CMs and facilitated
their use in a disease model of HCM. The advance in culture
conditions toward a fully defined formulation also revealed the
potential of the single-cell traction force measurement technol-
ogy for studying diseases of contractility in a highly controllable
system.742 Cell Reports 13, 733–745, October 27, 2015 ª2015 The AuthorsEXPERIMENTAL PROCEDURES
hPSC Culture and Differentiation
H3 NKX2-5eGFP/w hESCs or M1 NKX2-5eGFP/w hESCs as previously generated
(Elliott et al., 2011) were maintained on mouse embryonic fibroblasts
and passaged using TrypLE select (Life Technologies). The generation of
transgene-free hiPSCs from skin fibroblasts of one healthy male donor
(LUMC0004iCtrl [Con1]) and three patients each with a c.2373dupG mutation
in MYBPC3 (LUMC0033iMyBPC [HCM1], LUMC0034iMyBPC [HCM2], and
LUMC0035iMyBPC [HCM3]) was previously reported (Dambrot et al., 2014).
A second transgene-free control hiPSC line (LUMC0047iCtrl [Con2]) generated
from another healthy male donor was included in this study. hiPSCs were
maintained on Matrigel (growth factor reduced; Corning 354230) in mTeSR1
medium (Stem Cell Technologies) and passaged with 1 mg/ml Dispase (Life
Technologies). NKX2-5eGFP/w hiPSCs (R.P.D. and C.L.M., unpublished data)
were maintained in Essential 8 medium (Life Technologies) and differentiated
as previously described (van den Berg et al., 2015).
Cardiac differentiation was induced from monolayer cultures on Matrigel in
a serum-free medium (BSA, polyvinyl alcohol, essential lipids [BPEL]) as
described in the Supplemental Information. Contracting cultures were dissoci-
ated on day 13 and replated on Matrigel-coated 24-well plates. The following
experimental factors were added on day 16, refreshed on day 20, and
measured on day 21: 100 ng/ml Long R3 IGF-1 (in the main text: IGF-1),
1 mMSAG (Millipore), 1 mMdexamethasone, 100 nM triiodothyronine hormone,
10 mM phenylephrine, 1 mM isoproterenol, and 1-1000 nM norepinephrine.
Unless otherwise stated, all factors were obtained from Sigma-Aldrich.
The composition of the defined cardiomyocyte medium used in the
MYBPC3 shRNA experiment can be found in the Supplemental Information.
Lentiviral Transduction
shRNAs againstMYBPC3 (NM_000256) were obtained fromOpen Biosystems
in the pLKO vector (1, TRCN0000082906; 2, TRCN0000082903). A scrambled
shRNA was used as control (Sarbassov et al., 2005) (Addgene plasmid: 1864).
Cardiomyocytes were transduced with lentiviruses on day 15 of differentiation
and subsequently selected with puromycin before single-cell dissociation
and measurement. Protein knockdown was assessed by western blot as
described in the Supplemental Information.
Flow Cytometry Measurements for Plasma Membrane Potential and
Reactive Oxygen Species
For relative plasma membrane potential measurement, differentiated cultures
were dissociated on day 21 (after treatment as above from day 16) using 53
TrypLE Select and resuspended in 2.5 nM TMRM (Life Technologies) in
warm assay medium. Cells were incubated for 8 min at 37C before being
measured by flow cytometry. For superoxide detection, dissociated cells
were labeled with 5 mM DHE for 30 min at 37C and then measured by flow
cytometry. Appropriate compensation to correct from cross-bleed was per-
formed for each.
Respiration and Acidification Rates Measured with the Seahorse
XF Analyzer
Respiration and acidification rates were measured using a Seahorse XF-24 or
an XF-96 Analyzer (Seahorse Bioscience). Cells were seeded on Matrigel-
coated assay plates 7 days before measurement. The assay was performed
in bicarbonate-free DMEM as described in the Supplemental Information.
Cells were washed twice and pre-incubated in the assay medium for 1 hr
before measurement. For the standard profiling, oligomycin was used at
0.5 mg/ml, FCCP titrated in two injections to 3 mM, and rotenone and antimycin
A were added at 1 and 2 mM, respectively. A standard protein assay was used
to normalize values to whole-cell protein. Glycolytic rate calculations and ATP
production rates are described in the Supplemental Information. To assess
ATP demand for excitation and contractility, nifedipine (10 mM) and blebbista-
tin (5 mg/ml) were co-injected, and the respiration rate was immediately re-
corded, followed by measurements after oligomycin and then rotenone and
antimycin A injection. A vehicle-only injection was performed in parallel and
the effect was subtracted. Experiments analyzing the effect of etomoxir
and UK5099 were performed on the XF-96 format using an assay medium
with the following modifications: the glucose concentration was 5.5 mM, so-
dium pyruvate 0.15 mM, and palmitic acid was included at 100 mM conjugated
to fatty-acid-free BSA as described in the Supplemental Information. 10 mM
HEPES was also included in this assay medium to provide extra buffering
(glycolytic rates were not calculated). Cells were pre-incubated in this assay
medium for 4 hr before measurement. To assess the response to substrate up-
take inhibitors, 40 mM etomoxir or 5 mM UK5099 was injected, and respiration
rates were recorded after 45 min, followed by injections of oligomycin, FCCP,
and then rotenone and antimycin A. A vehicle-only injection was performed in
parallel, and the effect was subtracted.
Electrophysiological Characterization
Action potential (AP) recordings were performed on single cardiomyocytes,
6–10 days after cell dissociation with the amphotericin perforated patch-
clamp technique using an Axopatch 200B amplifier (Molecular Devices Cor-
poration). Signals were filtered and digitized at 5 and 40 kHz, respectively.
Data acquisition and analysis were accomplished using pClamp10.1 (Axon
Instruments) and custom software. Potentials were corrected for the liquid
junction potential. Cells were continuously perfused in a perfusion chamber
at 37C (Cell MicroControls) using Tyrode’s solution containing (mM) NaCl
140, KCl 5.4, CaCl2 1.8, MgCl2 1.0, glucose 5.5, HEPES 5 (pH 7.4) (NaOH).
Pipettes (borosilicate glass; resistance 2.5 MU) were filled with solution
containing (mM) K-gluconate 125, KCl 20, NaCl 5, amphotericin-B 0.22,
HEPES 10 (pH 7.2) (KOH).
APs were recorded at spontaneous frequencies and characterized by dura-
tion at 50% and 90% repolarization (APD50 and APD90, respectively),
maximal diastolic potential (MDP), AP amplitude, maximal upstroke velocity,
and frequency. AP parameter values obtained from eight to nine consecutive
APs were averaged, and data were collected from at least two independent
differentiations per condition.
The SGK1 inhibitor GSK650394 (Sherk et al., 2008) or vehicle-only control
was applied at 6 mM 5 days before AP measurement. AP measurements
were blinded in acquisition and analysis.
Traction Force Measurements
The traction force measurements were performed as previously described
(Hazeltine et al., 2012). Cells were seeded on gelatine patterned acrylamide
gels (see the Supplemental Information) 4 days before and measured in their
normal culture medium in an environment at 37C with 5% CO2. An image
series of aligned single spontaneously contracting cardiomyocytes was
taken at 403 magnification at 20 frames per second, recording bright-field
and fluorescent beads. Single frames from maximal relaxation and contrac-
tion of the bright-field and fluorescent beads image-series were analyzed by
the LIBTRC software package (kindly provided by Dr. Micah Dembo),
creating a mask of the cell outline from the bright-field image and a vector
map from the difference between the relaxed and contracted fluorescent
beads images. The vector map and the cell mask were used to calculate
the maximum total force that the cell applies on the substrate. The traction
stress generated by the cardiomyocyte during contraction was calculated
by dividing the total force by the cell-surface area. Measurements were
blinded in acquisition and analysis.
Quantitative Real-Time PCR
RNA was isolated with a Minelute RNA extraction kit (QIAGEN) and cDNA
synthesized using an iScript cDNA synthesis kit (Bio-Rad). Real-time PCR
was performed on a Bio-Rad CFX384 machine using IQ SYBR Green (Bio-
Rad). Gene expression values were normalized to the mean expression of
the housekeeping genes human ribosomal protein (RPLP0), glucuronidase
(GUSB), and RNF7. Primer sequences can be found in the Supplemental
Information.
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